埃塞俄比亚耐多药结核病死亡病例描述

IF 1.3 Q4 RESPIRATORY SYSTEM Public Health Action Pub Date : 2023-12-01 DOI:10.5588/pha.23.0030

Usaid Emawayish Tesema, Z. Dememew, D. G. Datiko, A. Gebreyohannes, Y. Molla, A. Tefera, G. Gizatie, T. Bogale, M. Million, P. G. Suarez, M. M. Aseressa, D. Jerene, M. Biru

{"title":"埃塞俄比亚耐多药结核病死亡病例描述","authors":"Usaid Emawayish Tesema, Z. Dememew, D. G. Datiko, A. Gebreyohannes, Y. Molla, A. Tefera, G. Gizatie, T. Bogale, M. Million, P. G. Suarez, M. M. Aseressa, D. Jerene, M. Biru","doi":"10.5588/pha.23.0030","DOIUrl":null,"url":null,"abstract":"Deaths related to multidrug-resistant TB among patients who had received a second-line anti-TB drugs in Ethiopia were analysed. Respectively 38/704 (5.4%) and 44/995 (4.4%) deaths were identified in two cohorts (2015 and 2022). In the 2015 cohort, severe malnutrition was less prevalent, previous treatment rates were three times higher, hypokalaemia was more frequent, and the use of the Xpert® MTB/RIF assay, respiratory failure and severe anaemia/pancytopenia were less common than in the 2022 cohort. We observed that there were variations in adverse events when different treatment regimens were used over different time periods. To ensure proper patient care, correct guidance must be consistently implemented.","PeriodicalId":46239,"journal":{"name":"Public Health Action","volume":" 5","pages":"123 - 125"},"PeriodicalIF":1.3000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Descriptors of multidrug-resistant TB deaths in Ethiopia\",\"authors\":\"Usaid Emawayish Tesema, Z. Dememew, D. G. Datiko, A. Gebreyohannes, Y. Molla, A. Tefera, G. Gizatie, T. Bogale, M. Million, P. G. Suarez, M. M. Aseressa, D. Jerene, M. Biru\",\"doi\":\"10.5588/pha.23.0030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Deaths related to multidrug-resistant TB among patients who had received a second-line anti-TB drugs in Ethiopia were analysed. Respectively 38/704 (5.4%) and 44/995 (4.4%) deaths were identified in two cohorts (2015 and 2022). In the 2015 cohort, severe malnutrition was less prevalent, previous treatment rates were three times higher, hypokalaemia was more frequent, and the use of the Xpert® MTB/RIF assay, respiratory failure and severe anaemia/pancytopenia were less common than in the 2022 cohort. We observed that there were variations in adverse events when different treatment regimens were used over different time periods. To ensure proper patient care, correct guidance must be consistently implemented.\",\"PeriodicalId\":46239,\"journal\":{\"name\":\"Public Health Action\",\"volume\":\" 5\",\"pages\":\"123 - 125\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Public Health Action\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5588/pha.23.0030\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Action","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/pha.23.0030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

对埃塞俄比亚接受二线抗结核药物治疗的患者中与耐多药结核病相关的死亡进行了分析。在2015年和2022年两个队列中分别发现38/704(5.4%)和44/995(4.4%)例死亡。在2015年队列中，严重营养不良的发生率较低，既往治疗率高出3倍，低钾血症更为频繁，Xpert®MTB/RIF检测的使用，呼吸衰竭和严重贫血/全血细胞减少症的发生率低于2022年队列。我们观察到，当不同的治疗方案在不同的时间段使用时，不良事件有所不同。为了确保适当的病人护理，必须始终如一地实施正确的指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Descriptors of multidrug-resistant TB deaths in Ethiopia

Deaths related to multidrug-resistant TB among patients who had received a second-line anti-TB drugs in Ethiopia were analysed. Respectively 38/704 (5.4%) and 44/995 (4.4%) deaths were identified in two cohorts (2015 and 2022). In the 2015 cohort, severe malnutrition was less prevalent, previous treatment rates were three times higher, hypokalaemia was more frequent, and the use of the Xpert® MTB/RIF assay, respiratory failure and severe anaemia/pancytopenia were less common than in the 2022 cohort. We observed that there were variations in adverse events when different treatment regimens were used over different time periods. To ensure proper patient care, correct guidance must be consistently implemented.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Public Health Action RESPIRATORY SYSTEM-

自引率

0.00%

发文量

期刊介绍： Launched on 1 May 2011, Public Health Action (PHA) is an official publication of the International Union Against Tuberculosis and Lung Disease (The Union). It is an open access, online journal available world-wide to physicians, health workers, researchers, professors, students and decision-makers, including public health centres, medical, university and pharmaceutical libraries, hospitals, clinics, foundations and institutions. PHA is a peer-reviewed scholarly journal that actively encourages, communicates and reports new knowledge, dialogue and controversy in health systems and services for people in vulnerable and resource-limited communities — all topics that reflect the mission of The Union, Health solutions for the poor.